The stock broke a resistance level yesterday with huge volume
Buy - $12 (yesterday)
Target - $28
Not a recommendation of course
There are always opportunities... you just have to know where to find them (-:
NASDAQ:IOVA
IOVA has doubled in February and broke out above its volume profile high volume area about
one week ago as it runs to earnings. Since it settled down two days ago into a relative side-
ways consolidation. I will take a long trade here for a pre-earnings play to presume that the
buying and bullish momentum will resume nearly immediately.
In a significant stride towards revolutionizing cancer treatment, Iovance Biotherapeutics, Inc. (NASDAQ: NASDAQ:IOVA ) has achieved a monumental milestone. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Iovance's AMTAGVI™ (lifileucel) suspension for intravenous infusion, marking a groundbreaking advancement in the fight against...
Analyzing the options chain of IOVA Iovance Biotherapeutics prior to the earnings report this week,
I would consider purchasing the 7.5usd strike price Puts with
an expiration date of 2023-6-16,
for a premium of approximately $0.70
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read...
This is not a financial advice!
I see first a pullback coming, w8 for it and watch PA closely before entering.
Most info on the chart.
Trade carefully!
IOVA formed a large bearish Rising Wedge on this Weekly timeframe
This has led to a big downward move, which correlates well with the rising wedge, being a primarily bearish pattern
Support has yet to be found on the Weekly timeframe
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic...
Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer.
Let's start with a weekly chart (not a logarithm). There are 2 relative bullish divergences, we are also not in a bad zone of the horizontal and inclined trend (depends on whether 2019 candles are considered a puncture). Bearish divergence is also present, but perhaps we will win back it. There are also hidden bulls on the monthly. Fibo levels in chart options...
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary...
COMPLETE UPDATE FOR IOVA.
Notes: The difference between complete draft and incomplete draft is basically blind spots that show up on different looks. Anyway, under 35 is moderately strong buy for 43-44 late January or early February.
THE LIGHT GRAY ROUTE IS TECHNICALLY DRAFT 1 EVEN THOUGH I DIDN'T CALL IT THAT.
Notes: I started this for a request a while ago, but noticed that its strong bounce after the recent sell off (bad news from FDA or something like that) had real volume structure that is ahead of price. That is to say that this is a strong stock that may catch all sorts of fire after...
was a good buy in the 30-32 range but i still think it's a buy here too, institutional interest, everyone likes it, i think it's headed to 40 within a month no prob unless the market tanks, also think it's good long term hold unless the story changes
